首页> 外文期刊>Trials >Dupuytren’s interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial
【24h】

Dupuytren’s interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial

机译:Dupuytren的干预措施手术与胶原酶(碟)试验:用于务实,双臂平行组,非劣级随机对照试验的研究方案

获取原文
           

摘要

Dupuytren’s contracture is a fibro-proliferative disease of the hands affecting over 2 million UK adults, particularly the white, male population. Surgery is the traditional treatment; however, recent studies have indicated that an alternative to surgery—collagenase clostridium histolyticum (collagenase)—is better than a placebo in the treatment of Dupuytren’s contracture. There is however no robust randomised controlled trial that provides a definitive answer on the clinical effectiveness of collagenase compared with limited fasciectomy surgery. Dupuytren’s intervention surgery vs collagenase trial (DISC) trial was therefore designed to fill this evidence gap. The DISC trial is a multi-centre pragmatic two-arm parallel-group, randomised controlled trial. Participants will be assigned 1:1 to receive either collagenase injection or surgery (limited fasciectomy). We aim to recruit 710 adult participants with Dupuytren’s contracture. Potential participants will be identified in primary and secondary care, screened by a delegated clinician and if eligible and consenting, baseline data will be collected and randomisation completed. The primary outcome will be the self-reported patient evaluation measure assessed 1 year after treatment. Secondary outcome measures include the Unité Rhumatologique des Affections de la Main Scale, the Michigan Hand Questionnaire, EQ-5D-5L, resource use, further procedures, complications, recurrence, total active movement and extension deficit, and time to return to function. Given the limited evidence comparing recurrence rates following collagenase injection and limited fasciectomy, and the importance of a return to function as soon as possible for patients, the associated measures for each will be prioritised to allow treatment effectiveness in the context of these key elements to be assessed. An economic evaluation will assess the cost-effectiveness of treatments, and a qualitative sub-study will assess participants’ experiences and preferences of the treatments. The DISC trial is the first randomised controlled trial, to our knowledge, to investigate the clinical and cost-effectiveness of collagenase compared to limited fasciectomy surgery for patients with Dupuytren’s contracture. Clinical.Trials.gov ISRCTN18254597 . Registered on April 11, 2017.
机译:Dupuytren的挛缩是一种手中的纤维增殖疾病,影响了200多万英国成年人,特别是白人人口。手术是传统治疗;然而,最近的研究表明,在治疗Dupuytren挛缩的安慰剂中,替代手术 - 胶原酶蛋白酶蛋白酶组织(胶原酶)的替代方案。然而,没有强大的随机对照试验,可以对胶原酶的临床效果提供明确的答案与有限的Fasciecectomy手术相比。因此,Dupuytren的干预手术与胶原酶试验(光盘)试验旨在填补这一证据差距。光盘试验是一个多中心的务实双臂并联组,随机对照试验。参与者将被分配1:1以接受胶原酶注射或手术(有限的Fasciececectomy)。我们的目标是招募710名成年参与者与Dupuytren的挛缩。潜在的参与者将在初级和二级护理中确定,由委派临床医生筛选,如果符合条件和同意,将收集基线数据并完成随机化。主要结果将是治疗后1年评估的自我报告的患者评估措施。次要结果措施包括单位rhumatologique des感情de la主规模,密歇根手调查问卷,eq-5d-5l,资源使用,进一步的程序,复杂性,复发,总主动运动和延伸赤字,以及返回功能的时间。鉴于胶原酶注射液后复发率和有限的Fasciectomy的复发率的有限证据,以及恢复功能尽快患者,每个人的相关措施将优先考虑允许在这些关键要素的背景下进行治疗效果评估。经济评估将评估治疗的成本效益,定性分布将评估参与者的经验和治疗的偏好。光盘试验是我们所知的第一个随机对照试验,探讨胶原酶的临床和成本效益与Dupuytren的挛缩患者有限的Fasciectomy手术相比。临床.Trials.gov ISRCTN18254597。 2017年4月11日注册。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号